TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline <i>BRCA</i> Carriers With HER2-Negative Breast Cancer (the INFORM trial)

Nadine Tung, Banu Arun, Michele R. Hacker, Erin Hofstatter, Deborah L. Toppmeyer, Steven J. Isakoff, Virginia Borges, Robert D. Legare, Claudine Isaacs, Antonio C. Wolff, Paul Kelly Marcom, Erica L. Mayer, Paulina B. Lange, Andrew J. Goss, Colby Jenkins, Ian E. Krop, Eric P. Winer, Stuart J. Schnitt, Judy E. Garber

Open source

DOI: 10.1200/jco.19.03292
Published: 2020-05-10
Container: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco.19.03292,
  title = {TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline
                    <i>BRCA</i>
                    Carriers With HER2-Negative Breast Cancer (the INFORM trial)},
  author = {Nadine Tung and Banu Arun and Michele R. Hacker and Erin Hofstatter and Deborah L. Toppmeyer and Steven J. Isakoff and Virginia Borges and Robert D. Legare and Claudine Isaacs and Antonio C. Wolff and Paul Kelly Marcom and Erica L. Mayer and Paulina B. Lange and Andrew J. Goss and Colby Jenkins and Ian E. Krop and Eric P. Winer and Stuart J. Schnitt and Judy E. Garber},
  year = {2020},
  journal = {Journal of Clinical Oncology},
  doi = {10.1200/jco.19.03292},
  url = {https://doi.org/10.1200/jco.19.03292}
}

RIS

TY  - JOUR
TI  - TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline
                    <i>BRCA</i>
                    Carriers With HER2-Negative Breast Cancer (the INFORM trial)
AU  - Nadine Tung
AU  - Banu Arun
AU  - Michele R. Hacker
AU  - Erin Hofstatter
AU  - Deborah L. Toppmeyer
AU  - Steven J. Isakoff
AU  - Virginia Borges
AU  - Robert D. Legare
AU  - Claudine Isaacs
AU  - Antonio C. Wolff
AU  - Paul Kelly Marcom
AU  - Erica L. Mayer
AU  - Paulina B. Lange
AU  - Andrew J. Goss
AU  - Colby Jenkins
AU  - Ian E. Krop
AU  - Eric P. Winer
AU  - Stuart J. Schnitt
AU  - Judy E. Garber
PY  - 2020
JO  - Journal of Clinical Oncology
DO  - 10.1200/jco.19.03292
UR  - https://doi.org/10.1200/jco.19.03292
ER  -

APA

Tung, N., Arun, B., Hacker, M. R., Hofstatter, E., Toppmeyer, D. L., Isakoff, S. J., Borges, V., Legare, R. D., Isaacs, C., Wolff, A. C., Marcom, P. K., Mayer, E. L., Lange, P. B., Goss, A. J., Jenkins, C., Krop, I. E., Winer, E. P., Schnitt, S. J., & Garber, J. E. (2020). TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline <i>BRCA</i> Carriers With HER2-Negative Breast Cancer (the INFORM trial). Journal of Clinical Oncology. https://doi.org/10.1200/jco.19.03292

Source records

crossref · retrieved 2026-09-26T01:15:24.738Z